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ABSTRACT Idiopathic pulmonary fibrosis (IPF) is an incurable, progressive interstitial lung disease with
a prognosis that is worse than that of many cancers. Epidemiological studies have demonstrated a link
between IPF and thrombotic vascular events. Coagulation and fibrinolytic systems play central roles in
wound healing and repair, processes hypothesised to be abnormal within the IPF lung. Animal models of
pulmonary fibrosis have demonstrated an imbalance between thrombosis and fibrinolysis within the
alveolar compartment, a finding that is also observed in IPF patients. A systemic prothrombotic state also
occurs in IPF and is associated with increased mortality, but trials of anticoagulation in IPF have provided
conflicting results. Differences in methodology, intervention and study populations may contribute to the
inconsistent trial outcomes. The new oral anticoagulants have properties that may prove advantageous in
targeting both thrombotic risk and progression of lung fibrosis.
@ERSpublications
A review of the coagulation system in IPF exploring scientific and clinical studies in this area
http://ow.ly/OdXwX
Introduction
Idiopathic pulmonary fibrosis (IPF) is a devastating disease with a 5-year survival that is worse than that
of many cancers. Despite extensive research in recent years, the underlying pathophysiology is
incompletely understood, and diagnostic and management decisions are made in the context of a
multidisciplinary team [1]. Epidemiological studies have revealed a link between IPF and thrombotic
vascular diseases including deep vein thrombosis (DVT), pulmonary embolism (PE) and acute coronary
syndromes (ACS) [2–4]. Animal models of fibrosis have demonstrated an imbalance between thrombosis
and fibrinolysis, which is also seen in the alveolar compartment in IPF patients [5, 6]. Recent studies have
shown a systemic pro-thrombotic state in IPF [7], but clinical trials of anticoagulation have provided
conflicting results [8, 9]. This review will discuss the role of the coagulation system in IPF, appraise the
findings of the two clinical trials of anticoagulation in IPF and explore a role for new anticoagulants.
Epidemiology of IPF and thrombosis
HUBBARD et al. [2] investigated the link between IPF and cardiovascular disease in a population-based
study using a large general practice database. They included 920 IPF subjects and 3593 matched controls,
and studied the prevalence of cardiovascular disease, cerebrovascular disease and DVT. They reported an
increased risk of ACS (OR 1.53, 95% CI 1.15–2.03) and DVT (OR 1.98, 95% CI 1.13–3.48) in subjects
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who subsequently developed IPF [2]. The risk increased further following IPF diagnosis (rate ratio for
ACS: 3.14, 95% CI 2.02–4.87; rate ratio for DVT: 3.39, 95%CI 1.57–7.28).
Studies in Denmark [3] and the USA [4] have confirmed these findings. SODE et al. [3] used national
registries to identify 19557 patients with idiopathic interstitial pneumonia (IIP) and over 7 million
controls. The same registries were used to identify subjects with venous thromboembolism (VTE) events.
The hazard ratio (HR) for developing IIP in those with VTE was 1.8 (95% CI 1.7–1.9) and was higher in
those with PE (HR 2.4, 95% CI 2.3–2.6) than in those with DVT (HR 1.3, 95% CI 1.2–1.4). Again, it was
noted that VTE appeared to precede the diagnosis of IIP. To assess the specificity of these observations,
SPRUNGER et al. [4] used US cause-of-death registries to identify IPF cases and three comparison groups:
population-based controls, chronic obstructive pulmonary disease (COPD) patients without IPF and lung
cancer patients without IPF. A total of 218991 cases of IPF were identified with a VTE prevalence of
1.74%. This was significantly greater than among population-based controls, for whom the incidence was
1.31% (adjusted OR 1.34, 95% CI 1.29–1.38). A similar increased risk of VTE was associated with IPF
compared with COPD (adjusted OR 1.41, 95% CI 1.31–1.46) and lung cancer patients (adjusted OR 1.66,
95% CI 1.61–1.72). VTE was less prevalent in the COPD and lung cancer groups than in the general
population, contrasting with previous reports of increased VTE risk in these populations [10].
Despite the inherent limitations of large epidemiological studies, the reproducible demonstration of
increased risk of vascular events in IPF patients across three large datasets from different populations
provides compelling evidence of an association.
Coagulation and the alveolar compartment
Maintaining vascular integrity and patency is essential to survival, and is achieved through haemostasis. A
shift in the balance between thrombus formation and fibrinolysis can lead to pathological vessel occlusion
or bleeding. A simplified scheme of the coagulation cascade is presented in figure 1.
The pro-fibrotic potential of coagulation factors and the role of protease-activated receptors (PARs) in
mediating thrombin-induced fibroblast proliferation and extracellular matrix deposition in experimental
models of pulmonary fibrosis have been reviewed previously [11].
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FIGURE 1 A simplified representation of the coagulation cascade. Activation through intrinsic or extrinsic pathways
leads to production of thrombin from prothrombin and subsequent conversion of fibrinogen to fibrin monomers that
link together to make the stable fibrin clot. The fibrinolytic system breaks down cross-linked fibrin polymers through
activation of plasminogen to plasmin. Fibrinolysis is controlled by the balance between plasminogen activators
(urokinase and tissue plasminogen activator (tPA)) and plasminogen activator inhibitors (PAI-1 and PAI-2). TF: tissue
factor; TFPI: tissue factor pathway inhibitor.
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Elevated levels of tissue factor (TF) and plasminogen activator inhibitor (PAI) have been demonstrated in
the mouse lung following bleomycin exposure, with alveolar macrophages and type II alveolar epithelial
cells implicated in their production [12]. These factors have been studied in the IPF alveolar compartment
(fig. 2) [5, 13, 14].
TF is a 43-kDa transmembrane cell surface glycoprotein that forms a complex with factor VIIa. Tissue
factor pathway inhibitor (TFPI) inhibits the action of TF/factor VIIa complex [5]. TF has been shown to
be elevated in bronchoalveolar lavage (BAL) fluid of patients with biopsy proven IPF, with the highest
levels seen in patients with severe, progressive disease [5, 6]. Although TFPI is also elevated in the BAL
fluid of IPF patients, the balance is in favour of a procoagulant state [5]. Immunostaining revealed TF and
TFPI in alveolar epithelial cells and macrophages in IPF patients, but not in controls [5].
Plasmin, produced from plasminogen in response to plasminogen activator, is a broad spectrum protease
that is important in fibrinolysis but is also capable of degrading other extracellular proteins that leak into
the alveolar space during alveolar injury [15]. In health, there is an abundance of urokinase plasminogen
activator (uPA) in the alveolar compartment, favouring fibrinolysis [16]. However, BAL fluid from IPF
patients shows increased levels of PAIs [6], with immunostaining demonstrating a similar pattern to that
of TF [5, 6, 17]. In the bleomycin mouse model of pulmonary fibrosis, the degree of PAI-1 gene
expression positively correlated with lung collagen deposition, supporting a relationship between PAI and
fibrosis [15]. Therefore, the alveolar compartment in IPF patients favours activation of the coagulation
cascade through elevated TF levels and impaired fibrinolysis. Similar findings have been observed in adult
respiratory distress syndrome (ARDS) [16, 18].
Systemic hypercoagulability
Platelets
Platelets circulate in a resting state, becoming activated in response to endogenous agonists (e.g. thrombin,
collagen and ADP). In health, platelets rapidly activate and aggregate at the site of vascular injury to
maintain vessel integrity but this also occurs in thrombotic vascular disease. In addition to their role in
haemostasis, platelets are important in mediating immune responses and tissue repair [19].
The relationship between platelets and the lung in health and in acute lung injury has previously been
reviewed [19]. It is important to note that platelet formation and removal occurs within the lung [20, 21],
and increased platelet activation has been demonstrated in a number of respiratory diseases including
ARDS and COPD [19, 22].
Activation of platelets results in degranulation. Platelet α-granules contain platelet-derived growth factor
[23] and transforming growth factor-β [24], both of which are implicated in animal models of pulmonary
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FIGURE 2 The alveolar compartment in idiopathic pulmonary fibrosis (IPF). Tissue factor (TF) is elevated to a greater
extent than tissue factor pathway inhibitor (TFPI) resulting in a procoagulant state. In health, urokinase plasminogen
activator (uPA) is abundant. However, elevated plasminogen activator inhibitor (PAI) in IPF prevents plasmin
production reducing fibrinolysis and favouring fibrin deposition.
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fibrosis and IPF [25–27]. Mice given intravenous bleomycin exhibited platelet sequestration within the
lungs that correlated with collagen deposition, supporting a role for platelets in fibrosis [28]. Indeed, FAHIM
et al. [29] reported increased platelet–monocyte interactions (a sensitive marker of platelet activation) in
patients with IPF compared with non-IPF interstitial lung disease (ILD) and non-ILD controls. Platelets
are implicated in the pathogenesis of ARDS, with increased surface P-selectin expression on circulating
platelets and demonstration of platelet microthrombi in the pulmonary microvasculature [30]. Acute
exacerbations of IPF are associated with a histological pattern indistinguishable from that of the diffuse
alveolar damage seen in ARDS or acute lung injury. The demonstration of abnormal platelet responses in
stable IPF patients raises the question of whether recurrent occult lung injury is resulting in a low-grade
fibrotic response in contrast to the fulminant reaction seen in ARDS. Investigation of platelet responses in
IPF patients represents an interesting new avenue of research.
The coagulation cascade and fibrinolysis
The end result of coagulation system activation is fibrin clot formation. Each fibrin monomer is composed
of a single E-domain and two D-domains. During fibrin clot formation, a covalent bond is formed
between adjacent D-domains, forming the D-dimer antigen. During plasmin-mediated fibrinolysis, the
D-dimer antigen is exposed and can be detected using commercially available assays.
Several studies have examined D-dimer concentration in IPF patients. A trial of anticoagulation in
IPF measured plasma D-dimer on study entry and reported an elevated mean concentration of
1.9–2.1 μg·mL−1 (reference range <0.5 μg·mL−1) [8]. Among patients admitted with an acute exacerbation
of IPF during the study, those who died were noted to have significantly higher levels of elevated D-dimer
than those who survived (mean±SD 3.3±2.3 μg·mL−1 versus 0.9±0.7 μg·mL−1; p<0.0001) [8]. A subsequent
trial of warfarin in IPF reported mean±SD baseline D-dimer concentrations of 0.9±1.69 μg·mL−1 in the
warfarin group and 0.5±0.3 μg·mL−1 in the placebo group [9], although the laboratory reference range and
method of analysis were not described (published data report 0.5 μg·mL−1 as the upper limit for VTE
exclusion). These studies demonstrate that IPF patients have elevated D-dimer levels indicating increased
activation of the coagulation and fibrinolytic systems.
NAVARATNAM et al. [7] undertook a population-based study to identify if a prothrombotic state was
associated with the development and outcome of IPF. They assessed 211 incident IPF cases and 256
matched controls for the presence of a prothrombotic state, which was defined as the presence of at least
one out of 11 measured hereditary or acquired coagulation abnormalities. They found that IPF patients
were more likely to have a prothrombotic state than controls (OR 4.78, 95% CI 2.93–7.8). Elevated
D-dimer was more common in the IPF group (OR 1.69, 95% CI 1.09–2.62), but the striking difference was
elevated factor VIII levels (OR 7.02, 95% CI 4.29–11.5). Both of these measures demonstrated a stronger
association with IPF at higher levels. Previous smaller studies have demonstrated elevated factor VIIIc,
D-dimer, fibrinogen and homocysteine levels in IPF patients, with the highest levels observed in those with
an acute exacerbation [31].
Factor VIII exists in the plasma as a complex of proteins. Elevated factor VIII levels are a recognised risk
factor for arterial and venous thrombosis [32–35]; therefore, the observation of elevated levels in IPF
provides insight into the link with thrombotic vascular disease. However, the nature of the relationship in
the lung remains unclear. Elevated factor VIII levels are associated with endothelial injury [32–34] and
could occur secondary to the fibrotic process rather than contributing to IPF pathogenesis. The
prothrombotic state does appear to impact outcomes in IPF with NAVARATNAM et al. [7], reporting an
associated three-fold increase in mortality.
The utility of stratifying IPF patients based on markers of systemic hypercoagulability is untested, but the
observation that a prothrombotic state impacts IPF outcome suggests a potential role in prognostication
that may add to existing clinical risk prediction models [36]. Additionally, identifying IPF patients with a
prothrombotic state would allow anticoagulation to be targeted to those most likely to benefit. This
therapeutic approach may be desirable in IPF [37]. Conducting large clinical trials of individualised
therapies in IPF subgroups would require global collaboration in order to achieve adequate statistical
power, supporting the need for a global IPF registry [38].
Anticoagulation in IPF
In 2005, KUBO et al. [8] reported an open-label, randomised trial of prednisolone plus anticoagulant
therapy versus prednisolone alone in IPF patients. A striking improvement in survival in the
anticoagulation group provided hope that treating hypercoagulability in IPF may improve outcomes.
However, a subsequent double-blind, randomised, placebo-controlled trial of anticoagulation with warfarin
in IPF demonstrated increased mortality in the anticoagulation group [9], with the excess deaths largely
due to progressive lung disease. The key features of the studies are outlined in table 1.
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The study by KUBO et al. [8] was significantly limited by its small sample size, lack of blinding, absence of
a true placebo-controlled arm and failure to analyse on an intention-to-treat basis, making it difficult to
draw conclusions. By contrast, the negative outcome of the larger, randomised, double-blind,
placebo-controlled trial of warfarin therapy allows a firm conclusion to be drawn that warfarin therapy is
potentially harmful in IPF where there is no other indication for anticoagulation.
Warfarin has been associated with other organ system dysfunction including renal impairment.
Warfarin-related nephropathy is characterised by an increase in serum creatinine following periods where
the international normalised ratio exceeds the therapeutic range [39]. A case series of nine patients with
acute kidney injury and haematuria following warfarin overdose demonstrated widespread glomerular
haemorrhage with obstructive red cell casts on biopsy [40]. A larger study of 15258 patients initiated on
warfarin did not demonstrate any increase in haematuria in those that developed nephropathy, indicating
that organ dysfunction can occur without overt bleeding [39]. This poses the question of whether the
IPF-related deaths in the warfarin group were due to occult alveolar haemorrhage. Although it seems
unlikely this would go undetected, it is unclear whether patients in this study underwent post mortem
examination [9].
Warfarin interferes with vitamin K metabolism, preventing the production of active (carboxylated) vitamin
K-dependent clotting factors. Vitamin K is also essential for the production of the endogenous
anticoagulant protein C. Homozygous protein C deficiency results in fatal thrombotic events in infancy
and heterozygotes have increased risk of VTE [41]. Initiation of warfarin therapy can result in protein C
deficiency before depletion of vitamin K-dependent clotting factors leading to a transient procoagulant
state. Protein C also exhibits cytoprotective properties through alteration of inflammatory and apoptotic
gene expression, downregulation of release of inflammatory mediators, reduced cell adhesion molecule
expression and maintenance of endothelial barrier function [41]. Interference with these protective
pathways could contribute to worse outcomes in IPF.
TABLE 1 Key features of two randomised trials of anticoagulation in idiopathic pulmonary
fibrosis
KUBO et al. [8] NOTH et al. [9]
Design Open label, randomised
controlled trial
Double-blind, randomised,
placebo-controlled trial
Site 5 hospitals in Japan 22 centres in North America
Subjects n 56 145
Intervention group 23 72
Control group 33 73
Intervention Prednisolone plus warfarin (target
INR 2.0–3.0) with intravenous LMWH
during exacerbation
Warfarin (target INR 2.0–3.0)
Control Prednisolone alone Sham, dose-adjusted placebo
Baseline FVC % predicted
Intervention group 69±13 59±16
Control group 71±17 59±16
Baseline TLCO % predicted
Intervention group 59±15 34±12
Control group 63±14 35±13
Follow-up days Median 347 (intervention)
Median 399 (controls)
Mean 196
Steroid Use 100 28
Patients with exacerbation
during follow-up
Intervention group 47.8 8.3
Control group 63.6 2.7
All-cause mortality during
follow-up
Intervention group 21.7 19.4
Control group 60.6 4.1
Data are presented as mean±SD or %, unless otherwise stated. FVC: forced vital capacity; TLCO: transfer
factor of the lung for carbon monoxide; INR: international normalised ratio; LMWH: low molecular weight
heparin.
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Although methodologically flawed, the magnitude of the signal observed in the study by KUBO et al. [8] is
hard to ignore. A notable feature of this study was the use of intravenous low molecular weight heparin
during admission for progressive respiratory failure. Indeed, the mortality rate from an acute exacerbation
of IPF in the anticoagulation group was comparatively low, at 18% compared with 71% in the
non-anticoagulation group [8], and a combined mortality rate of 63% in patients in both groups was seen
in the study by NOTH et al. [9]. Although the limitations of the study and the high rate of exacerbations
make it difficult to generalise these results to the IPF population as a whole, it raises questions about
whether warfarin is the correct anticoagulant to be studying in IPF and what is the best time to
anticoagulate patients? Some of the issues discussed in this section have been debated in correspondence
following the publication of the study by NOTH et al. [9] with all parties agreeing that further research is
required to examine the role of other anticoagulants in IPF [42].
New therapeutic targets
Two new groups of oral anticoagulants have recently been developed: direct thrombin inhibitors and direct
factor Xa inhibitors. At present, in Europe, their use is recommended for specific indications including
VTE prophylaxis following hip or knee replacement, stroke prevention in non-valvular atrial fibrillation
and treatment of VTE.
Dabigatran is an oral, direct thrombin inhibitor. Thrombin mediates fibrin production from fibrinogen,
activates platelets and induces differentiation of fibroblasts into myofibroblasts [43]. In vitro, dabigatran
has been shown to inhibit thrombin-induced fibroblast differentiation into myofibroblasts, and reduce
connective tissue growth factor and collagen production by lung fibroblasts [44]. Indeed, direct thrombin
inhibition has been shown to attenuate lung collagen deposition in the bleomycin mouse model of
pulmonary fibrosis [45, 46].
The direct factor Xa inhibitors, apixaban and rivaroxaban, have efficacy in preventing stroke and other
systemic emboli in patients with atrial fibrillation, and in the treatment of VTE [47–49]. Factor Xa
facilitates the production of thrombin from prothrombin and is increased in fibrotic lung tissue [50]. It
has been shown to promote fibroblast proliferation and differentiation in a thrombin-independent manner
through PAR-1 signalling, and direct factor Xa inhibition has been shown to attenuate fibrosis in the
bleomycin mouse model [50–52].
Therefore, these novel anticoagulants have potential antifibrotic properties in addition to their
anticoagulant effects, and their mechanism of action avoids the proposed negative effects of warfarin.
Investigation of their potential value in IPF is warranted.
Conclusions
There is compelling epidemiological evidence of an association between thrombotic vascular events and
IPF that is supported by biological demonstration of a local and systemic prothrombotic state, which
correlates with disease severity and clinical outcomes. While two clinical trials of anticoagulation in IPF
have reported conflicting results, it can be concluded that manipulation of the coagulation system plays a
role in IPF pathogenesis. Further research is required to delineate the mechanisms underlying the
prothrombotic state in IPF, to assess the utility of phenotyping patients based on thrombotic tendency and
to evaluate the new classes of anticoagulants in IPF.
References
1 Cottin V. Current approaches to the diagnosis and treatment of idiopathic pulmonary fibrosis in Europe: the AIR
survey. Eur Respir Rev 2014; 23: 225–230.
2 Hubbard RB, Smith C, Le Jeune I, et al. The association between idiopathic pulmonary fibrosis and vascular
disease: a population-based study. Am J Respir Crit Care Med 2008; 178: 1257–1261.
3 Sode BF, Dahl M, Nielsen SF, et al. Venous thromboembolism and risk of idiopathic interstitial pneumonia: a
nationwide study. Am J Respir Crit Care Med 2010; 181: 1085–1092.
4 Sprunger DB, Olson AL, Huie TJ, et al. Pulmonary fibrosis is associated with an elevated risk of thromboembolic
disease. Eur Respir J 2012; 39: 125–132.
5 Fujii M, Hayakawa H, Urano T, et al. Relevance of tissue factor and tissue factor pathway inhibitor for
hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis. Thromb Res 2000; 99: 111–117.
6 Kotani I, Sato A, Hayakawa H, et al. Increased procoagulant and antifibrinolytic activities in the lungs with
idiopathic pulmonary fibrosis. Thromb Res 1995; 77: 493–504.
7 Navaratnam V, Fogarty AW, McKeever T, et al. Presence of a prothrombotic state in people with idiopathic
pulmonary fibrosis: a population-based case-control study. Thorax 2014; 69: 207–215.
8 Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128:
1475–1482.
9 Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary
fibrosis. Am J Respir Crit Care Med 2012; 186: 88–95.
DOI: 10.1183/16000617.00008414 397
COAGULATION AND ANTICOAGULATION IN IPF | M.G. CROOKS AND S.P. HART
10 Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients
with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore)
1999; 78: 285–291.
11 Chambers RC. Role of coagulation cascade proteases in lung repair and fibrosis. Eur Respir J 2003; 22: Suppl. 44,
33s–35s.
12 Wygrecka M, Markart P, Ruppert C, et al. Cellular origin of pro-coagulant and (anti)-fibrinolytic factors in
bleomycin-injured lungs. Eur Respir J 2007; 29: 1105–1114.
13 Chapman HA, Allen CL, Stone OL. Abnormalities in pathways of alveolar fibrin turnover among patients with
interstitial lung disease. Am Rev Respir Dis 1986; 133: 437–443.
14 Wygrecka M, Kwapiszewska G, Jablonska E, et al. Role of protease-activated receptor-2 in idiopathic pulmonary
fibrosis. Am J Respir Crit Care Med 2011; 183: 1703–1714.
15 Eitzman DT, McCoy RD, Zheng X, et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either
lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97: 232–237.
16 Bertozzi P, Astedt B, Zenzius L, et al. Depressed bronchoalveolar urokinase activity in patients with adult
respiratory distress syndrome. N Engl J Med 1990; 322: 890–897.
17 Senoo T, Hattori N, Tanimoto T, et al. Suppression of plasminogen activator inhibitor-1 by RNA interference
attenuates pulmonary fibrosis. Thorax 2010; 65: 334–340.
18 Idell S, Koenig KB, Fair DS, et al. Serial abnormalities of fibrin turnover in evolving adult respiratory distress
syndrome. Am J Physiol 1991; 261: L240–L248.
19 Bozza FA, Shah AM, Weyrich AS, et al. Amicus or adversary: platelets in lung biology, acute injury, and
inflammation. Am J Respir Cell Mol Biol 2009; 40: 123–134.
20 Zucker-Franklin D, Philipp CS. Platelet production in the pulmonary capillary bed: new ultrastructural evidence
for an old concept. Am J Pathol 2000; 157: 69–74.
21 Tabuchi A, Kuebler WM. Endothelium-platelet interactions in inflammatory lung disease. Vascul Pharmacol 2008;
49: 141–150.
22 Maclay JD, McAllister DA, Johnston S, et al. Increased platelet activation in patients with stable and acute
exacerbation of COPD. Thorax 2011; 66: 769–774.
23 Kaplan DR, Chao FC, Stiles CD, et al. Platelet alpha granules contain a growth factor for fibroblasts. Blood 1979;
53: 1043–1052.
24 Fava RA, Casey TT, Wilcox J, et al. Synthesis of transforming growth factor-β1 by megakaryocytes and its
localization to megakaryocyte and platelet alpha-granules. Blood 1990; 76: 1946–1955.
25 Antoniades HN, Bravo MA, Avila RE, et al. Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin
Invest 1990; 86: 1055–1064.
26 Sime PJ, Xing Z, Graham FL, et al. Adenovector-mediated gene transfer of active transforming growth factor-β1
induces prolonged severe fibrosis in rat lung. J Clin Invest 1997; 100: 768–776.
27 Cao B, Guo Z, Zhu Y, et al. The potential role of PDGF, IGF-1, TGF-β expression in idiopathic pulmonary
fibrosis. Chin Med J (Engl) 2000; 113: 776–782.
28 Piguet PF, Vesin C. Pulmonary platelet trapping induced by bleomycin: correlation with fibrosis and involvement
of the β2 integrins. Int J Exp Pathol 1994; 75: 321–328.
29 Fahim A, Crooks MG, Morice AH, et al. Increased platelet binding to circulating monocytes in idiopathic
pulmonary fibrosis. Lung 2014; 192: 277–284.
30 Tomashefski JF Jr, Davies P, Boggis C, et al. The pulmonary vascular lesions of the adult respiratory distress
syndrome. Am J Pathol 1983; 112: 112–126.
31 Bargagli E, Madioni C, Bianchi N, et al. Serum analysis of coagulation factors in IPF and NSIP. Inflammation
2014; 37: 10–16.
32 Greaves M, Pickering C, Knight G, et al. Changes in the factor VIII complex in diabetic ketoacidosis: evidence of
endothelial cell damage? Diabetologia 1987; 30: 160–165.
33 Carvalho AC, Bellman SM, Saullo VJ, et al. Altered factor VIII in acute respiratory failure. N Engl J Med 1982;
307: 1113–1119.
34 Grant K, Rodvien R, Mielke CH Jr. Altered factor VIII complexes in patients with acute respiratory insufficiency.
Thromb Haemost 1978; 40: 326–334.
35 Kamphuisen PW, Eikenboom JC, Bertina RM. Elevated factor VIII levels and the risk of thrombosis. Arterioscler
Thromb Vasc Biol 2001; 21: 731–738.
36 Kolb M, Collard HR. Staging of idiopathic pulmonary fibrosis: past, present and future. Eur Respir Rev 2014; 23:
220–224.
37 Maher TM. Disease stratification in idiopathic pulmonary fibrosis: the dawn of a new era? Eur Respir J 2014; 43:
1233–1236.
38 Ryerson CJ, Corte TJ, Collard HR, et al. A global registry for idiopathic pulmonary fibrosis: the time is now. Eur
Respir J 2014; 44: 273–276.
39 Brodsky SV, Nadasdy T, Rovin BH, et al. Warfarin-related nephropathy occurs in patients with and without
chronic kidney disease and is associated with an increased mortality rate. Kidney Int 2011; 80: 181–189.
40 Brodsky SV, Satoskar A, Chen J, et al. Acute kidney injury during warfarin therapy associated with obstructive
tubular red blood cell casts: a report of 9 cases. Am J Kidney Dis 2009; 54: 1121–1126.
41 Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109: 3161–3172.
42 Bendstrup E, Hillberg O. Is warfarin the right anticoagulant in idiopathic pulmonary fibrosis? Am J Respir Crit
Care Med 2012; 186: 693.
43 Bogatkevich GS, Tourkina E, Silver RM, et al. Thrombin differentiates normal lung fibroblasts to a myofibroblast
phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway. J Biol Chem
2001; 276: 45184–45192.
44 Bogatkevich GS, Ludwicka-Bradley A, Silver RM. Dabigatran, a direct thrombin inhibitor, demonstrates
antifibrotic effects on lung fibroblasts. Arthritis Rheum 2009; 60: 3455–3464.
45 Howell DC, Goldsack NR, Marshall RP, et al. Direct thrombin inhibition reduces lung collagen, accumulation, and
connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. Am J Pathol 2001; 594:
1383–1395.
398 DOI: 10.1183/16000617.00008414
COAGULATION AND ANTICOAGULATION IN IPF | M.G. CROOKS AND S.P. HART
46 Bogatkevich GS, Ludwicka-Bradley A, Nietert PJ, et al. Antiinflammatory and antifibrotic effects of the oral direct
thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease. Arthritis Rheum 2011; 63:
1416–1425.
47 Jalota A, Scarabelli TM, Saravolatz L, et al. Novel anticoagulants for stroke prevention in patients with atrial
fibrillation. Cardiovasc Drugs Ther 2014; 28: 247–262.
48 Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of
symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies.
Thromb J 2013; 11: 21.
49 Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J
Med 2013; 369: 799–808.
50 Scotton CJ, Krupiczojc MA, Königshoff M, et al. Increased local expression of coagulation factor X contributes to
the fibrotic response in human and murine lung injury. J Clin Invest 2009; 119: 2550–2563.
51 Blanc-Brude OP, Chambers RC, Leoni P, et al. Factor Xa is a fibroblast mitogen via binding to effector-cell
protease receptor-1 and autocrine release of PDGF. Am J Physiol Cell Physiol 2001; 281: C681–C689.
52 Blanc-Brude OP, Archer F, Leoni P, et al. Factor Xa stimulates fibroblast procollagen production, proliferation, and
calcium signaling via PAR1 activation. Exp Cell Res 2005; 304: 16–27.
DOI: 10.1183/16000617.00008414 399
COAGULATION AND ANTICOAGULATION IN IPF | M.G. CROOKS AND S.P. HART
